Cost-effectiveness of risk assessment and tailored treatment for peripheral arterial disease patients

A. Vaidya*, M.A. Joore, A.J. ten Cate-Hoek, H. ten Cate, J.L. Severens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Aim: The objective of this study was to explore the cost-effectiveness of D-dimer biomarker and the societal value (headroom) of a hypothetical perfect biomarker for risk assessment and subsequent treatment stratification of prophylactic treatment for peripheral arterial disease (PAD). Patients & methods: Decision analytic modeling. Results: Use of the D-dimer biomarker to prescribe oral anticoagulants in the high-risk subset of patients is a cost-effective healthcare intervention. The headroom (societal willingness to pay multiplied by incremental quality-adjusted life years) available for the hypothetical perfect biomarker amounted to (sic)83,877. Conclusion: D-dimer-based PAD risk assessment and treatment tailoring is cost effective. Identification of high-risk PAD patients and prescription of oral anticoagulants could potentially save substantial costs and improve chances of survival for high-risk PAD patients. However, further research of risk stratifying biomarkers test accuracy is needed to support and strengthen the results of this modeling study.
Original languageEnglish
Pages (from-to)989-999
Number of pages11
JournalBiomarkers in Medicine
Issue number8
Publication statusPublished - 1 Jan 2014


  • cost-effectiveness analysis
  • D-dimer
  • decision modeling
  • peripheral arterial disease
  • risk assessment


Dive into the research topics of 'Cost-effectiveness of risk assessment and tailored treatment for peripheral arterial disease patients'. Together they form a unique fingerprint.

Cite this